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INTRODUCTION

Mutations of
α spectrin (Sp) involving the Sp heterodimer self-association site (the α I domain of Sp) represent the most common group of erythrocyte membrane defects in hereditary elliptocytosis (HE) and a closely related disorder, hereditary pyropoikilocytosis (HPP; acronym HP also used). 1, 2 HPP is characterized by extreme microcytosis with unique poikilocytic microspherocytic morphology; it is typically found among people of African origin and rarely among Caucasians. 3 The molecular defects underlying HPP are spectrin deficiency 4 and a severe Sp dimer (SpD) self-association defect, 5 which weaken the erythrocyte skeleton and cause membrane instability. Mutations that interfere with Sp tetramer (SpT) assembly typically occur in the α Sp gene (SPTA) and HPP subjects are heterozygous, doubly heterozygous or homozygous for these mutations that cause structural defects in the protein. 1, 6 In addition, HPP is associated with a second defect, which results in a decreased amount of the α Sp peptide.
Several molecular mechanisms have been described that underlie this partial Sp deficiency.
These include defective α Sp mRNA accumulation indicative of a malfunction in RNA processing: 7 increased degradation of α Sp prior to incorporation into the membrane; 8 reduced levels of α Sp mRNA and decreased synthesis of α Sp protein; 8 and a splicing abnormality resulting in a premature stop codon. 9 The clinical severity of HE/HPP is influenced by the precise location and type of the structural α Sp mutation, 6 as well as by the inheritance of modifying alleles, such as the hypomorphic SPTA α LELY polymorphism. 10 The SPTA SpD resulting in a reduced amount of α Sp peptide from this locus. 10 Inheritance of SPTA
cis to a SPTA R28H HE allele results in mild clinical symptoms, 11 whereas inheritance in trans causes a relative increase in the mRNA produced from the HE α Sp allele, which exacerbates the SpD self-association defect and may lead to the HPP phenotype. 10 Thus the increased proportion of defective α β SpD causes a more severe morphological and clinical phenotype.
Here we describe two Utah families of northern European descent with a novel SPTA R34P gene mutation interacting with four distinct αSp molecular configurations resulting in three phenotypes ranging from HPP to HE to normal morphology. Furthermore, the HPP phenotype is normocytic and not microcytic, and there are also numerous elliptocytes present on the peripheral smear, hence, we designate it as atypical HPP. In this manuscript, we elucidate the molecular basis of these three phenotypes associated with the novel SPTA R34P mutation and provide new insight into the complexity of erythrocyte membrane disorders.
METHODS
Clinical and routine laboratory studies
All patients provided written, informed consent before participation in the study. The studies were approved by University of Utah Institutional Review Board (IRB_00027669).
Family A
A 79-year old man (propositus of family A, A-I-3, Figure 1A ) presented with a life-long history of anemia and intermittent jaundice. He and his extended family trace their ancestry to Scottish and Scandinavian forebears who were among the first Mormon settlers of Utah Territory. He had a splenectomy two years prior to presentation that resulted in a partial amelioration of his anemia. He was aware that multiple family members had a history of abnormal red blood cell morphology and some were anemic. His erythrocyte morphology revealed anisopoikilocytosis, fragmented cells, microspherocytes, elliptocytosis and polychromasia ( Figure 3A ). 11 firstdegree relatives of his extended family over three generations were evaluated ( Figure 1A ).
Family B
An apparently unrelated 39 year old female (propositus of family B, B-I-1, Figure 2A ) was referred to us (JTP) for evaluation of very high platelet count and suspected essential thrombocythemia. As red cell fragmentation can be mistakenly reported as elevated platelet count by laboratory instruments, the accuracy of elevated platelet count has been verified by semi-quantitative estimation of platelet count by microscopic evaluation of blood smear by one of us experienced with RBC fragmentation in several HPP patients identified over last 3 decades (JTP). She had neonatal hyperbilirubinemia, and since birth has had episodes of jaundice with severe anemia (hemoglobin 70g/L). She had undergone splenectomy three years earlier, with improved anemia and no further episodes of jaundice. Her ancestors were also among the first Mormon settlers of Utah Territory and were of northern European ancestry. After splenectomy, she has had persistently elevated platelet counts (up to 1 million/μL) and was assumed to have essential thrombocythemia and treated intermittently with hydroxyurea. Her physical examination was unremarkable. Peripheral smear revealed significant anisopoikilocytosis, microspherocytes, elliptocytosis, and polychromasia ( Figure 3B ). Further studies revealed polyclonal hematopoiesis determined by the X-chromosome transcriptional assay 12 and the absence of JAK2 and cMPL somatic mutations. The clinical diagnosis of atypical HPP and secondary thrombocytosis due to hemolytic anemia and splenectomy was made. Ten first-degree relatives of her extended family over two generations were evaluated ( Figure 2A ).
The age, sex, blood counts and erythrocyte morphology of all individuals who were studied from these two unrelated families are shown in Supplementary Table 1.
Molecular and expression studies of the SPTA locus
Quantitation of the SPTA mRNA transcript
Reticulocyte SPTA mRNA was purified and levels were determined as described in the Online Supplementary Methods section.
13,14
SPTA locus genotyping
Genotyping of the SPTA locus was performed using the SNP markers, rs857677and rs2251969, flanking the SPTA α LELY exon 40 and intron 45 mutations and two internal markers, rs3737515
and rs1616 (Applied Biosystems, CA, USA).
Erythrocyte membrane protein analysis
Membranes were prepared and the proteins subjected to SDS-PAGE and densitometric quantitation. 5 The details of this method are described in the Online Supplementary Methods section.
15,16
Comparative modelling of the spectrin tetramerization site
The details of this method are described in the Online Supplementary Methods section.
RESULTS
A novel SPTA
R34P mutation
Sequencing of the SPTA gene revealed heterozygosity for a novel missense mutation at exon 2, allele. In addition, the latter genotype was also found in one individual (A-II-4) with no discernible red cell defect and normal blood counts (see Figures 1A and 2A ). These findings were confirmed on repeated testing. (Table 1A and 1B). Eleven normal family members from the two pedigrees had normal SpD values and a normal SpαI domain.
Erythrocyte membrane skeleton analyses
Model of the Sp tetramerization site
A Figure 4G ) and the helical propensity of the polypeptide is decreased (Supplementary Table 3 ).
Quantitation of α
Sp mRNA
The effect of the SPTA α LELY allele is to reduce the amount of Sp peptide from this locus.
Inheritance of SPTA α LELY in trans to an HE allele results in a more severe phenotype by increasing the relative quantity of defective Sp peptide by a posttranslational mechanism. All subjects who inherited the SPTA R34P mutation in trans to SPTA α LELY had a greater level of mutant exon 2 mRNA compared to wild type at a ratio approximating 3:1 (Table 1A and The amount of total SPTA transcript produced in reticulocytes was also measured and this showed that in all HE subjects the level of SPTA mRNA was decreased to ~85% of controls, whereas in all individuals with normal morphology the expression level was unaffected (Table   1A and 1B). Both HPP subjects had markedly decreased levels of total SPTA reticulocyte mRNA (~10% of normal).
Molecular studies of the SPTA locus
Incongruous results were obtained for individual B-II-7 and his mother, B-I-3, who both had an HE phenotype and were heterozygous for the SPTA R34P mutation. The mother had the SPTA α LELY polymorphism on her normal (R34) allele and since her son did not have this allele, he presumably inherited the wild type allele from his father (not available for study). His mother would thus have passed on the mutant SPTA R34P allele to him, however, the haplotype of this SPTA R34P allele was different to that of his mother and required further investigation ( Figure 2A ).
Intragenic crossover and uniparental disomy
Informative SNP analysis was performed on the SPTA locus of subject B-II-7 to establish his haplotype and to compare it to the haplotype of his mother (B-I-3) and two available siblings (the father's DNA was unavailable). An intragenic crossover was found, which resulted in loss of heterozygosity (LOH) most likely from uniparental disomy (UPD) and homozygosity for the wild-type exon 40 (C) and intron 45 (C) allele without the SPTA α LELY mutations present in his mother ( Figure 5 ). We couldn't formally exclude the possibility that this observed LOH was not due to LOH from deletion; unfortunately this could not be formally tested because of the limited amount of DNA available.
Segregation of the SPTA α
LELY mutations
The haplotype of individual B-I-3 further revealed a novel segregation of the two SPTA α LELY mutations since she had wild-type exon 40 (C), but mutant intron 45 (T). Her nephew, B-II-1, also showed separation of the two mutations, but in this case he had the exon 40 mutation (G) and wild type intron 45 (C) (Figure 2A ). This is the first reported instance where these two mutations have not been inherited together and presumably reflects additional examples of intragenic crossover of this large gene.
DISCUSSION
HPP has a striking morphological phenotype which, although very rare, has been of intense interest to hematologists. Its characteristic features are severe microcytosis and spherocytes with unusual poikilocytic projections. While it is almost always found in Blacks and occasionally in people of Mediterranean origin, it has not been described among Northern Europeans. We have previously reported that, in some families, the HPP abnormality clusters with relatives who either have HE or who exhibit a normal hematological phenotype. 5, 17 However, a detailed analysis of the erythrocyte membrane skeleton revealed subtle functional and structural defects in Sp in those individuals with normal hematological indices, indicating that they are asymptomatic carriers. 5, 17 The molecular basis of the diverse phenotypes present in a single family is still poorly understood. Most of the mutations associated with the HE/HPP phenotype are missense mutations, generally in exon 2 of the SPTA gene, which impair the formation of αβSp heterotetramers. However, for the HPP phenotype, an additional hypomorphic mutation is thought to be necessary, which results in partial spectrin deficiency.
The SPTA R34P mutation perturbs the Sp tetramerisation site
The two HPP/HE families of northern European descent we describe here have a novel exon 2 SPTA R34P mutation. Arginine 34 is located in αSp repeat 0 and it interacts with key residues on βSp repeat 17 to stabilize the interface of the hybrid SpT. 18, 19 Mutation of this charged, basic residue to a compact, uncharged and cyclic proline, reduces the helical content of the repeat (Supplementary Table 3 ) and perturbs the interaction between Sp heterodimers as shown by molecular modeling (Figure 4 ).
Numerous missense mutations have been described in αSp repeat 0, but none involve proline. In contrast, the majority of pathogenic mutations in the helical linker regions between αSp repeats are due to proline substitutions, which cause unfolding of the links and destabilization of the adjacent repeats. 20 These long-range effects on SpT formation imply that the structural consequences of helix-breaking proline mutations are quite severe. In these families we report here, the effect of the SPTA R34P mutation is relatively mild, causing an increase in SpD of only ~25%, when inherited without other modifying alleles (A-II-4). This biochemical defect is insufficient to affect erythrocyte morphology and subject A-II-4 is an asymptomatic carrier with a normal hematological phenotype.
One other pathogenic mutation has been described at amino acid 34 of αSp (SPTA R34W ), which caused mild elliptocytosis in a single family. 21 The Evolutionary sequence analysis revealed that arginine 34 is a highly conserved residue, although some species diversity exists, for example, glutamine is present in rat and mouse αSp. These combined data support the findings in this study, which indicate that even though the SPTA R34P mutation perturbs SpT formation, it is not severe enough to cause clinical symptoms in the absence of hypomorphic modifier alleles.
At present, we do not have any data about the frequency of this novel SPTA R34P mutation in the Utah population. The propositi of both currently studied families, although not known to be related, have ancestry originating among the early Mormon settlers in Utah. As a large proportion of the Utah population trace their ancestry from these early Mormons, our report of affected individuals may indicate that the SPTA R34P mutation represents a founder effect in this Mormon community.
Intragenic Sp crossover
An additional novel finding in one of the HE subjects, B-II-7, was an intragenic crossover manifesting as a LOH, most likely generated by UPD in the SPTA gene in the region between exon 40 and intron 45. We acknowledge that this observed LOH could not formally exclude a deletion as a mechanism of LOH; however this deletion would likely result in a more pronounced RBC membrane disarray than only HE seen in our patient. In point of fact a recent report 23 indicated that such a large deletion would result in a striking morphological abnormality.
This LOH resulted in the loss of the SPTA α LELY allele, but the exon 2 SPTA R34P mutation was unaffected. To further characterize this UPD, presumably originating from the father's SPTA gene (father's DNA not available), haplotype analysis was performed using additional polymorphic markers, defining this SPTA UPD as "BCAC", which replaces the "ACAT" Subject B-I-3 has the SPTA α LELY allele in trans to the SPTA R34P mutation, but has also gained the intron 45 mutation in cis to the codon 34 mutation, so both alleles will be produced in reduced amounts.
Decreased expression of αSp mRNA in reticulocytes
All ten subjects who were heterozygous for the SPTA R34P mutation have unequal levels of αSp mRNA from the two alleles, with the P34 mutant allele accounting for ~70% of the αSp mRNA in reticulocytes. Seven of these subjects inherited the hypomorphic SPTA These anomalies highlight our limited knowledge of modifying factors that influence the transcription and translation of αSp.
Quantitation of the total amount of reticulocyte αSp mRNA revealed normal amounts in the asymptomatic carrier, but this was reduced to ~85% for all HE subjects. Since αSp peptides are produced in a two to three fold excess over βSp 8 , the rate limiting step in αβSp heterodimer formation is the synthesis of βSp and a slight reduction in αSp mRNA should not have an effect on the Sp content of the erythrocyte membrane. For the two HPP propositi, however, only 10%
αSp mRNA was present in reticulocytes and this resulted in a partial deficiency of Sp. However, we submit that this transcriptional defect of αSp gene is a pivotal contribution to the described phenotype, thus the accuracy of this important observation has been confirmed several times using separately obtained blood specimens. Currently the molecular basis of this phenomenon remains unexplained. It may be due to mutation in the promoter region of this gene (not detected) or it also may be due to aberrant regulatory molecules controlling α Sp transcription, such as microRNA or other regulatory noncoding RNAs, or an abnormal transcription factor, such as described with a GATA1 mutation causing multiple phenotypes 25 . Unfortunately, fresh blood samples from these propositi are no longer available for studies designed to address these possibilities.
Genotype -phenotype correlations
The novel SPTA R34P mutation in the two Utah families reported here is associated with unexpected genotypic and phenotypic heterogeneity ( Table 2) . Three distinct phenotypes of atypical HPP, HE, and an asymptomatic carrier state with normal erythrocyte morphology were observed. The HPP propositi exhibited the typical spherocytic poikilocytosis diagnostic of this disorder, but elliptocytes were also present on the peripheral blood smears, and unlike other HPP subjects, they were not microcytic. Biochemically they showed the characteristic protein defects of markedly reduced αβSp heterodimer self-association, a reduced proportion of Sp oligomers, an abnormal tryptic digest pattern, and partial Sp deficiency.
The clinical expression of an elliptocytogenic αSp mutation is influenced by the coinheritance of hypomorphic alleles such as SPTA α LELY , which exacerbates the clinical phenotype, when inherited in trans to the mutant allele, as evidenced in the two propositi and HE subjects AI-1, AII-2, AII-6 and AIII-1 (Table 2 ). However, HE subjects A-III-2 and B-II-7 lacked the SPTA α LELY polymorphism, but were clinically similarly affected. In addition, subject B-I-3 was homozygous for the intron 45 mutation, which would cause low expression of both mutant and wild type alleles and thus eliminate the effect. This study demonstrates that in these two families SPTA α LELY is not the only modifying allele influencing hematological parameters. A key additional factor modulating clinical presentation is the level of total αSp mRNA in reticulocytes, which correlates with the phenotype (Table 2 ).
In conclusion, in these two Utah families a novel SPTA R34P mutation is present in combination with four distinct genetic/biochemical defects: 1) inheritance in trans of either the hypomorphic SPTA α LELY or 2) the wild type SPTA allele; 3) an as yet unexplained decrease of total αSp transcripts and 4) a unique intragenic crossover (Table 2) . These different interactions between the SPTA locus and modifying alleles/factors provide the basis for all three distinct morphological phenotypes and offer an illuminating example of unanticipated complexity of inherited hematological disorders that stem from a single gene locus.
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TABLES
SUPPLEMENTARY MATERIALS AND METHODS
Genomic DNA
Genomic DNA was isolated from blood leukocytes using the Puregene DNA purification kit (Gentra, MN, USA). Exon 2 of the SPTA gene was amplified by PCR and sequenced using a 3130 Genetic Analyzer (Applied Biosystems, CA, USA). Primer sequences were described previously.
22
Reticulocyte mRNA
Total RNA was isolated from reticulocytes as previously described. The RNA precipitate was further purified using Tri-Reagent (Molecular Research Center, OH, USA) and reverse transcribed using Superscript III First-Strand Synthesis SuperMix including random primers (Invitrogen, CA, USA).
Quantitation of the SPTA mRNA transcript
Reticulocyte SPTA mRNA levels were determined using TaqMan mRNA Expression Assays and normalized to an endogenous HPRT control (Applied Biosystems, CA, USA).
Quantitative allele-specific PCR (qRT-ASPCR) for αSp reticulocyte mRNA was performed on a 7500-Sequence Detection-System (Applied Biosystems, CA, USA)
according to a modification of a previously described method utilizing complementary oligonucleotides containing a locked nucleic acid and a mismatch primer. Screening for SPTAαLELY was performed as previously described. Primer sequences are listed in Supplementary Table 2 .
Erythrocyte membrane protein analysis
Red cell membranes were prepared as described 5 . Briefly, erythrocytes were lysed with a hypotonic buffer (3mM sodium phosphate, pH 8, 0.1mM EDTA, 0.1mM phenylmethylsulphonyl fluoride) and the ghosts were pelleted by centrifugation at 30,000g
for 15 minutes at 4ºC and washed until clear of hemoglobin. The protein concentration was determined using the Coomassie Plus™ Protein Assay Reagent (Pierce Biotechnology Incorporated, USA). Aliquots were solubilized by boiling for 1 minute in 10mM Tris-HCl pH 8, 1mM EDTA, 1% SDS, 5% sucrose, 2% β-mercaptoethanol and 20-25μg protein resolved on a 4-17% Fairbanks exponential gradient SDS-polyacrylamide gel. 15 Coomassie Blue stained gels were scanned on a Hoefer GS300 transmittance/reflectance scanning densitometer and the accompanying GS365W software (Hoefer Scientific Instruments, USA) and the ratio of spectrin to band 3 was quantified for each individual.
Spectrin was analysed as previously described 5, 6 . Briefly, spectrin was extracted from the membranes in a low ionic strength buffer of 0.1mM sodium phosphate, pH 8, 0.1mM EDTA, 0.1mM 1,4-dithiothreitol (Roche Diagnostics GMBH, Germany) at 4ºC
overnight. Aliquots of 10μg spectrin were resolved on 3% acrylamide/0.3% agarose nondenaturing gels and stained with Coomassie blue. The percentage spectrin dimers (SpD) out of total SpD and spectrin tetramers (SpT) was determined by densitometry. Fifty micrograms spectrin was subjected to limited tryptic digestion with 0.5μg trypsin (SigmaAldrich Corporation, USA) for 18 hours at 4ºC and the peptides were resolved on a 10%
SDS-PAGE gel. 16 Relative amounts of the 80 and 74kDa peptides were determined by densitometry of the Coomassie-stained gels.
Comparative modeling of the spectrin tetramerization site
The crystal structure of the erythrocyte Sp tetramerization complex 19 is available in the Protein Data Bank (http://www.rcsb.org; accession number 3LBX). A putative model of the partial repeat 0 of helix C of αSp with the R34P mutation was generated using the Protein homology/analogy recognition engine V2.0 (Phyre2) algorithm (http://www.sbg.bio.ic.ac.uk/phyre2/) and the crystallized erythrocyte Sp tetramerization complex as a template. The model quality was assessed using the Qmean server (http://swissmodel.expasy.org/qmean/cgi/index.cgi). The model of the mutant Sp tetramerisation site was superimposed on the crystallized erythrocyte Sp tetramerization complex structure using Swiss PDB viewer (http://spdbv.vital-it.ch/refs.html). Images were modified using Pymol Molecular Graphics System, version 1.3, Schrödinger, LLC.
The helical propensity of normal and mutant Sp was analysed using Agadir (http://agadir.crg.es/).
